Some of the key players operating in the global biotherapeutics cell line development market are Becton, Dickinson and Company; Beckman Coulter, Inc.; Boehringer lngelheim Group; Catalent, Inc.; and Lonza Group Ltd. Among them, Becton Dickinson offers products related to biotherapeutics cell line development under the BD Biosciences segment. The company’s customer base is comprised of clinics, hospitals, pharmaceutical and biotechnology companies, research, industrial, and food microbiology labs. The company’s main thrust has been on developing innovative products.
Beckman Coulter, Inc., another key player in the global market for biotherapeutics cell line development, has furthered its market position with strategic acquisitions and an expanding product portfolio. Germany-based Boehringer Ingelheim has resorted to strategic partnerships to enhance its market share. It has also expanded in developing economies such as China to improve its market standing.
This 104 page report gives readers a comprehensive overview of the Biotherapeutics Cell Line Development Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html
Registering a CAGR of 7.50% from 2015 to 2022, the global biotherapeutics cell line development market is anticipated to reach a value of US$100 mn by 2022.
Quick Uptake of ClonePix and FACS Makes Transfection the Dominant Segment
Based on the process, the global biotherapeutics cell line development market can be bifurcated into transfection and single cell cloning. Among the two, the single cell cloning dominates the market with a lion’s share in the revenue because of quick adoption of instruments such as ClonePix and FACS. ClonePix has been more widely adopted so far on account of a greater demand for automated systems over the traditional limited dilution method which soaks up a lot of time.
The market for transfection comprising of consumables is expected to outpace that of single cell cloning in terms of growth rate in the future. The revenue in this section was US$57.63 mn in 2015.
Geography-wise, North America has been a market leader so far and going forward, it is predicted to maintain its leading share. In 2015 its revenue was worth US$25.20 mn. Europe follows in the second position. Both the continents have been market leaders on account of their burgeoning geriatric population and rampant occurrence of different maladies. Rise in demand for protein therapeutics such as monoclonal antibodies is also predicted to generate demand for mammalian cell line development for biotherapeutics. Asia Pacific is poised for maximum growth on account of the increasing outsourcing of biotherapeutics manufacture to third parties in developing countries in the region, which is cost effective for companies.
Growing Elderly Population Susceptible to Different Maladies Driving Growth
As far as market drivers are concerned, a rising elderly population is at the forefront of bringing about growth. Highly susceptible to chronic, degenerative, and autoimmune diseases such as diabetes, cancer, and multiple sclerosis, their medical requirements is majorly contributing to the biotherapeutics and consequently cell line development market. Another factor driving the market is the demand for monoclonal antibodies (mAb). “Monoclonal antibodies are used in a wide range of therapeutic applications and to treat various diseases such as cancer, multiple sclerosis, asthma and rheumatoid arthritis. Demand for monoclonal antibodies is driven by the understanding of disease (target) and treatment (drug) at a molecular level,” elaborates the analyst of the TMR report.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Biotherapeutics Cell Line Development Market during 2015 – 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272
Countering the growth of the market is the dearth of skilled professionals to meet growing requirement for fast moving and technologically advanced pharmaceutical and biotechnology products. This in term acts as a deterrent for establishing off-shore research and development facilities. Another market deterrent is stringent regulations. “Several compliance guidelines with international standards are in place such as International Standards Organization (ISO) quality concepts to ensure safe biopharmaceuticals and the World Health Organization (WHO),” informs the lead analyst of the report.
This review is based on the findings of a TMR report titled “Biotherapeutics Cell Line Development Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2022.”